Aurora Cannabis Inc. (ACB.TO)
| Previous close | 7.80 |
| Open | 7.85 |
| Bid | 7.73 x 0 |
| Ask | 7.77 x 0 |
| Day's range | 7.64 - 7.87 |
| 52-week range | 3.84 - 12.85 |
| Volume | |
| Avg. volume | 786,083 |
| Market cap | 424.714M |
| Beta (5Y monthly) | 2.72 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.63 |
| Earnings date | 07 Nov 2024 - 11 Nov 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 9.50 |
PR NewswireAurora CEO Miguel Martin takes on additional role as Executive Chairman of Board of Directors
Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), a leading Canada-based global medical cannabis company, today announced the appointments of CEO Miguel Martin to the additional role of Executive Chairman and outgoing Chairman Ron Funk as Lead Independent Director. Both appointments follow unanimous votes by Aurora's Board and are effective immediately.
PR NewswireAurora Cannabis Advances Auto-Flowering Research, Unveiling Key Insights for Future Cultivation Excellence
Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) –the Canadian based leading global medical cannabis company, is pioneering ground-breaking research in auto-flowering technology. Auto-flowering is a genetic characteristic that automatically transitions the plant from the vegetative stage to the flowering stage rather than relying on changes in light cycles. This innovative work provides foundational insight on flowering mechanism in cannabis, which will support future breeding strategies, and can b
PR NewswireAurora Cannabis and Vectura Fertin Pharma, Inc. announce launch of novel Luo CBD lozenge
Aurora Cannabis Inc. ("Aurora") (NASDAQ: ACB) (TSX: ACB), a leading Canadian-based global medical cannabis company, and Vectura Fertin Pharma, Inc., an innovator in wellness and healthcare, are pleased to announce the launch of the newly developed Luo CBD lozenge.
